Evidence map›Paper›PMID 33357517›Full record

ReviewThe Lancet. Infectious diseases2021

A decentralised point-of-care testing model to address inequities in the COVID-19 response.

Belinda Hengel, Louise Causer, Susan Matthews, Kirsty Smith, Kelly Andrewartha, Steven Badman, Brooke Spaeth, Annie Tangey, Phillip Cunningham, Amit Saha and 7 more

Erratum issuedAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in The Lancet. Infectious diseases, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 34 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
34citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

34 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Review
  16. Article
  17. Article
  18. Article
  19. Observational
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

17 authors.

Belinda HengelKirby Institute, University of New South Wales, Sydney, NSW, Australia; School of Population and Global Health, University of Melbourne, Melbourne, VIC, Australia. Electronic address: bhengel@kirby.unsw.edu.au.
Louise CauserKirby Institute, University of New South Wales, Sydney, NSW, Australia.
Susan MatthewsInternational Centre for Point-of-Care Testing, Flinders University, Adelaide, SA, Australia.
Kirsty SmithKirby Institute, University of New South Wales, Sydney, NSW, Australia.
Kelly AndrewarthaInternational Centre for Point-of-Care Testing, Flinders University, Adelaide, SA, Australia.
Steven BadmanKirby Institute, University of New South Wales, Sydney, NSW, Australia.
Brooke SpaethInternational Centre for Point-of-Care Testing, Flinders University, Adelaide, SA, Australia.
Annie TangeyKirby Institute, University of New South Wales, Sydney, NSW, Australia.
Phillip CunninghamKirby Institute, University of New South Wales, Sydney, NSW, Australia; NSW State Reference Laboratory for HIV, St Vincent's Hospital, Sydney, NSW, Australia.
Amit SahaKirby Institute, University of New South Wales, Sydney, NSW, Australia.
Emily PhillipsInternational Centre for Point-of-Care Testing, Flinders University, Adelaide, SA, Australia.
James WardPoche Centre for Indigenous Health, The University of Queensland, St Lucia, QLD, Australia.
Caroline WattsKirby Institute, University of New South Wales, Sydney, NSW, Australia.
Jonathan KingKirby Institute, University of New South Wales, Sydney, NSW, Australia.
Tanya ApplegateKirby Institute, University of New South Wales, Sydney, NSW, Australia.
Mark ShephardInternational Centre for Point-of-Care Testing, Flinders University, Adelaide, SA, Australia.
Rebecca GuyKirby Institute, University of New South Wales, Sydney, NSW, Australia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The COVID-19 pandemic is growing rapidly, with over 37 million cases and more than 1 million deaths reported by mid-October, 2020, with true numbers likely to be much higher in the many countries with low testing rates. Many communities are highly vulnerable to the devastating effects of COVID-19 because of overcrowding in domestic settings, high burden of comorbidities, and scarce access to health care. Access to testing is crucial to globally recommended control strategies, but many communities do not have adequate access to timely laboratory services. Geographic dispersion of small populations across islands and other rural and remote settings presents a key barrier to testing access. In this Personal View, we describe a model for the implementation of decentralised COVID-19 point-of-care testing in remote locations by use of the GeneXpert platform, which has been successfully scaled up in remote Aboriginal and Torres Strait Islander communities across Australia. Implementation of the decentralised point-of-care testing model should be considered for communities in need, especially those that are undertested and socially vulnerable. The decentralised testing model should be part of the core global response towards suppressing COVID-19.

Indexed as

AustraliaAustralian Aboriginal and Torres Strait Islander PeoplesCOVID-19COVID-19 TestingHumansPandemicsPoint-of-Care SystemsPoint-of-Care Testing

Identifiers

PMID33357517
PMCPMC7758179

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.